ArticleNeurobiology of aging2016
Impaired fasting glucose is associated with increased regional cerebral amyloid.
Article in Neurobiology of aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Long-term Change in Physiological Markers and Cognitive Performance in Type 2 Diabetes: The Look AHEAD Study.The Journal of clinical endocrinology and metabolism · 2020Trial
- A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults.The American journal of clinical nutrition · 2017Trial
- Heat Therapy: Targeting Health, Disease, and Disability.Comprehensive Physiology · 2026Review
- Soluble and plaque amyloid associations with peripheral glucose dysregulation modulated by tau pathology in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Observational
- Association of type 2 diabetes treatment status with in vivo biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Metabolic dysfunction associates with neuroimaging measures of brain structure and connectivity.Frontiers in neuroscience · 2026Article
- Improving glycemic control via heat therapy in older adults at risk for Alzheimer's disease (FIGHT-AD): a pilot study.Journal of applied physiology (Bethesda, Md. : 1985) · 2025Article
- Causal effect of blood osteocalcin on the risk of Alzheimer's disease and the mediating role of energy metabolism.Translational psychiatry · 2024Article
- Observational
- Could Alzheimer's disease be a maladaptation of an evolutionary survival pathway mediated by intracerebral fructose and uric acid metabolism?The American journal of clinical nutrition · 2023Review
- Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study.Brain : a journal of neurology · 2023Article
- Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer's Disease.Frontiers in neuroscience · 2022Review
- Relationship of fasting glucose and longitudinal Alzheimer's disease imaging markers.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Metabolic Syndrome and Cognitive Function.Current cardiology reports · 2021Review
- High Glycemic Diet Is Related to Brain Amyloid Accumulation Over One Year in Preclinical Alzheimer's Disease.Frontiers in nutrition · 2021Article
- Metabolic syndrome and its components in relation to in vivo brain amyloid and neurodegeneration in late middle age.Neurobiology of aging · 2021Article
- Characterization of the Meal-Stimulated Incretin Response and Relationship With Structural Brain Outcomes in Aging and Alzheimer's Disease.Frontiers in neuroscience · 2020Article
- Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions.Frontiers in neuroscience · 2020Review
- Cerebral Fructose Metabolism as a Potential Mechanism Driving Alzheimer's Disease.Frontiers in aging neuroscience · 2020Article
- High-Normal Adolescent Fasting Plasma Glucose Is Associated With Poorer Midlife Brain Health: Bogalusa Heart Study.The Journal of clinical endocrinology and metabolism · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The Alzheimer's disease risk gene apolipoprotein E epsilon 4 (APOE ε4) is associated with increased cerebral amyloid. Although impaired glucose metabolism is linked to Alzheimer's disease risk, the relationship between impaired glycemia and cerebral amyloid is unclear. To investigate the independent effects of APOE ε4 and impaired glycemia on cerebral amyloid, we stratified nondemented subjects (n = 73) into 4 groups: normal glucose, APOE ε4 noncarrier (control [CNT]; n = 31), normal glucose, APOE ε4 carrier (E4 only; n = 14) impaired glycemia, APOE ε4 noncarrier (IG only; n = 18), and impaired glycemia, APOE ε4 carrier (IG+E4; n = 10). Cerebral amyloid differed both globally (p = 0.023) and regionally; precuneus (p = 0.007), posterior cingulate (PCC; p = 0.020), superior parietal cortex (SPC; p = 0.029), anterior cingulate (p = 0.027), and frontal cortex (p = 0.018). Post hoc analyses revealed that E4 only subjects had increased cerebral amyloid versus CNT globally and regionally in the precuneus, PCC, SPC, anterior cingulate, and frontal cortex. In IG only subjects, increased cerebral amyloid compared with CNT was restricted to precuneus, PCC, and SPC. IG+E4 subjects exhibited higher cerebral amyloid only in the precuneus relative to CNT. These results indicate that impaired glycemia and APOE ε4 genotype are independent risk factors for regional cerebral amyloid deposition. However, APOE ε4 and impaired glycemia did not have an additive effect on cerebral amyloid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.